FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Pillar Invest Corp

2. Date of Event Requiring Statement (MM/DD/YYYY)
7/23/2019 

3. Issuer Name and Ticker or Trading Symbol

IDERA PHARMACEUTICALS, INC. [IDRA]

(Last)        (First)        (Middle)

PILLAR INVEST OFFSHORE SAL STARCO CTR,, BLOC B, 3RD FLOOR, OMAR DAOUK STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

BEIRUT, M8 2020-3313       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   3418224   I   (1) See Footnote   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Consists of 56,100 shares held directly by Pillar Pharmaceuticals I, L.P. ("Pillar I"), 40,820 shares held directly by Pillar Pharmaceuticals II, L.P. ("Pillar II"), 49,780 shares held directly by Pillar Pharmaceuticals III, L.P. ("Pillar III"), 10,000 shares held directly by Pillar Pharmaceuticals IV, L.P. ("Pillar IV"), 105,000 shares held directly by Pillar Pharmaceuticals V, L.P. ("Pillar V"), 1,392,259 shares held directly by Pillar Pharmaceuticals 6, L.P. ("Pillar 6"), 1,684,494 shares held directly by Pillar Partners Foundation, L.P. ("Pillar Foundation"), 6,724 shares and 33,125 options (exercisable with 60 days) held directly by Youssef El Zein and 39,922 shares held directly by Abude Umari.
(2)  Pillar Invest Corporation ("Pillar GP"), is the general partner of Pillar I, Pillar II, Pillar III, Pillar IV, Pillar V, Pillar 6 and Pillar Foundation. Youssef El Zein and Abude Umari are directors of Pillar GP. By virtue of the relationships described in this footnote, Messrs. El Zein and Umari may be deemed to exercise voting and dispositive power with respect to the shares held directly by Pillar I, Pillar II, Pillar III, Pillar IV, Pillar V, Pillar 6, Pillar Foundation and indirectly by Pillar GP. Messrs. Umari and El Zein expressly disclaim beneficial ownership of any shares held directly by Pillar I, Pillar II, Pillar III, Pillar IV, Pillar V, Pillar 6, Pillar Foundation and indirectly by Pillar GP except to the extent of their pecuniary interest therein. Pillar I, Pillar II, Pillar III, Pillar IV, Pillar V, Pillar 6, Pillar Foundation and Pillar GP expressly disclaim beneficial ownership of any shares held directly by Messrs. Umari and El Zein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Pillar Invest Corp
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Pharmaceuticals I LP
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Pharmaceuticals II, L.P.
PILLAR INVEST OFFSHORE SAL, STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Pharmaceuticals III, L.P.
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Pharmaceuticals IV, L.P.
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Pharmaceuticals V LP
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Pharmaceuticals 6, L.P.
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Pillar Partners Foundation, L.P.
PILLAR INVEST OFFSHORE SAL STARCO CTR
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

Umari Abude
PILLAR INVEST OFFSHORE SAL STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X

ZEIN YOUSSEF EL
PILLAR INVEST OFFSHORE SAL, STARCO CTR,
BLOC B, 3RD FLOOR, OMAR DAOUK STREET
BEIRUT, M8 2020-3313
X


Signatures
Pillar Invest Corporation, /s/ Youssef El Zein, Authorized Person 8/5/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Idera Pharmaceuticals Charts.
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Idera Pharmaceuticals Charts.